Drug Search Results
Using advanced filters...
Advanced Search [+]

Muraglitazar

Alternative Names: muraglitazar, Pargluva
Clinical Status: Inactive
Latest Update: 2020-11-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: PPAR-a Agonist,PPAR-g Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Type 2 Diabetes|Dyslipidemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

CV168-062

P3

Completed

Type 2 Diabetes

2006-08-01

2022-05-04

Primary Endpoints|Treatments

CV168-006

P3

Completed

Type 2 Diabetes

2006-06-01

2019-03-21

Treatments

CV168-026

P3

Completed

Type 2 Diabetes

2006-05-01

2022-05-04

Primary Endpoints|Treatments

CV168-048

P3

Completed

Type 2 Diabetes

2006-03-01

2022-05-04

Primary Endpoints|Treatments

CV168-021

P3

Completed

Type 2 Diabetes

2005-11-01

2019-03-21

NCT00130806

P3

Terminated

Type 2 Diabetes

2005-11-01

2022-05-04

CV168-025

P3

Completed

Type 2 Diabetes

2005-03-01

2019-03-21

Treatments

CV168-008

P3

Completed

Dyslipidemia

None

2019-03-21

Treatments

CV168-022

P3

Completed

Type 2 Diabetes

None

2019-03-21

Treatments

CV168-018

P3

Completed

Type 2 Diabetes

None

2019-03-21

Treatments